Meta-analysis of efficacy of transcranial magnetic stimulation for the treatment of cognitive function and behavioral and psychological symptoms of dementia in patients with Alzheimer′s disease

doi:10.3969/j.issn.1674-8115.2021.07.014

Abstract

Abstract: Objective

·To evaluate the efficacy of transcranial magnetic stimulation (TMS) on cognitive function and behavioral and psychological of dementia (BPSD) in Alzheimer′s disease (AD) patients.

Methods

·Nine databases including China National Knowledge Infrastructure (CNKI), WanFang, VIP, Chinese Biomedical Literature Database (CBM), PubMed, Embase, the Cochrane Library and Chinese and American Clinical Trial Center were searched before November 2, 2019. English was searched with the topics of “Alzheimer′s disease” “transcranial magnetic stimulation” and “randomize controlled trial”, and free words were retrieved. Chinese was searched with the topics of “阿尔茨海默病”“经颅磁刺激”“随机对照试验”. According to the pre-established inclusion and exclusion criteria, the literatures were screened. RevMan 5.3 software was used. The standardized mean difference (SMD) was used as the effect value, and 95% confidence interval (CI) was used for interval estimation. Gradeprofile 3.2.2 software was used to evaluate the quality of evidence.

Results

·A total of 23 articles were included. In improving cognitive function, the evaluation results of AD Assessment Scale-Cognitive suggest that SMD of high frequency TMS group was -0.64 (95%CI -0.89 ? -0.40, P=0.000), SMD of low frequency TMS group was -0.58 (95%CI -1.12 ? -0.05, P=0.030). The Grade of evidence quality was very lower and lower respectively. When using Mini-Mental State Examination to evaluate cognitive function, it was divided into three subgroups according to TMS frequency (high or low, value) and treatment times. The results showed that SMD in high frequency TMS group was 1.30 (95% CI 0.76?1.85, P = 0.000), but no significant difference was found in low frequency group. The Grade of evidence quality were both very lower. In 5 Hz group, SMD was 3.99 (95%CI 0.81~7.16, P=0.010) and the Grade evidence quality grade was very low. In the group of treatment times >40 and ≤60, SMD was 3.28 (95%CI 1.67?4.90, P=0.000) and the Grade evidence quality grade was very low. In the aspect of improving BPSD, the Neuropsychiatric Inventory was used to evaluate, and the result was no statistically significant. The Grade evidence quality grade was very low. Behavioral Pathology in Alzheimer′s Disease Scale showed that SMD of high frequency group was -0.83 (95%CI -1.06? -0.60, P=0.000), and there was no significance in low frequency group.The Grade evidence quality grade were low and very low respectively.

Conclusion

·TMS could improve the cognitive function of patients with AD, and high frequency was better than low frequency. The quality of evidence was lower. Whether the BPSD of AD patients were effective needs further research. In the future, more high-quality clinical multicenter randomized controlled trails should be included to study the efficacy and safety of TMS in the treatment of AD, so as to provide guidance for clinical practice.

Key words: Alzheimer′s disease (AD), transcranial magnetic stimulation (TMS), cognitive function, behavioral and psychological symptoms of dementia (BPSD), meta-analysis, randomized controlled trial (RCT)

CLC Number:

R 749.1⁺⁶

Yi WANG, Cheng CHENG, Hong-yan SHEN, Hong-yan GAO, Yue-ning DAI, Zheng-hui YI. Meta-analysis of efficacy of transcranial magnetic stimulation for the treatment of cognitive function and behavioral and psychological symptoms of dementia in patients with Alzheimer′s disease[J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(7): 931-941.

Figures/Tables 11

TrendMD

References 29

1	Chakraborty S, Lennon JC, Malkaram SA, et al. Serotonergic system, cognition, and BPSD in Alzheimer's disease[J]. Neurosci Lett, 2019, 704: 36-44.
2	吴越, 徐文炜, 刘晓伟, 等. 不同频率重复经颅磁刺激对阿尔茨海默病患者认知功能的影响[J]. 实用医学杂志, 2015, 31(10): 1624-1627.
3	姚子英. 不同频率重复经颅磁刺激对阿尔茨海默病患者的影响[J]. 中国卫生标准管理, 2018, 9(15): 57-59.
4	杨婵娟, 张若曦, 方雅秀, 等. 重复经颅磁刺激对阿尔茨海默病患者精神行为症状的疗效分析[J]. 神经疾病与精神卫生, 2014, 14(5): 454-456.
5	Santos MDD, Cavenaghi VB, APMG Mac-Kay, et al. Non-invasive brain stimulation and computational models in post-stroke aphasic patients: single session of transcranial magnetic stimulation and transcranial direct current stimulation. A randomized clinical trial[J]. Sao Paulo Med J, 2017, 135(5): 475-480.
6	Cotelli M, Manenti R, Cappa SF, et al. Transcranial magnetic stimulation improves Naming in Alzheimer disease patients at different stages of cognitive decline[J]. Eur J Neurol, 2008, 15(12): 1286-1292.
7	Ahmed MA, Darwish ES, Khedr EM, et al. Effects of low versus high frequencies of repetitive transcranial magnetic stimulation on cognitive function and cortical excitability in Alzheimer's dementia[J]. J Neurol, 2012, 259(1): 83-92.
8	Rutherford G, Lithgow B, Moussavi Z. Short and long-term effects of rTMS treatment on Alzheimer's disease at different stages: a pilot study[J]. J Exp Neurosci, 2015, 9: 43-51.
9	尹刚, 姚长江. 重复经颅磁刺激对阿尔茨海默病患者认知功能的影响[J]. 中国康复, 2015, 30(3): 174-176.
10	Wu Y, Xu WW, Liu XW, et al. Adjunctive treatment with high frequency repetitive transcranial magnetic stimulation for the behavioral and psychological symptoms of patients with Alzheimer's disease: a randomized, double-blind, sham-controlled study[J]. Shanghai Arch Psychiatry, 2015, 27(5): 280-288.
11	过婷, 袁周玲, 武曙燕, 等. 重复经颅磁刺激联合多奈哌齐治疗阿尔茨海默病的临床对照研究[J]. 中国康复, 2016, 31(1): 54-56.
12	Lee J, Choi BH, Oh E, et al. Treatment of Alzheimer's disease with repetitive transcranial magnetic stimulation combined with cognitive training: a prospective, randomized, double-blind, placebo-controlled study[J]. J Clin Neurol, 2016, 12(1): 57-64.
13	吴越, 徐文炜, 刘晓伟, 等. 奥氮平联合重复经颅磁刺激治疗阿尔茨海默病精神行为症状的疗效和安全性[J]. 医药导报, 2016, 35(10): 1069-1072.
14	方璟, 邹成林, 张海锋, 等. 重复经颅磁刺激联合加兰他敏治疗阿尔茨海默病的疗效观察[J]. 蚌埠医学院学报, 2017, 42(8): 1025-1028.
15	刘艳华, 王丽娜, 边艳辉, 等. 不同频率重复经颅磁刺激对于老年痴呆患者的认知能力与精神行为症状的影响[J]. 国际精神病学杂志, 2017, 44(2): 263-266.
16	刘新, 侯前梅, 赵晓琼, 等. 10 Hz重复经颅磁刺激对轻中度阿尔茨海默病患者的精神行为症状及注意执行的疗效观察[J]. 川北医学院学报, 2017, 32(3): 376-379.
17	梁卫峰, 莫珠成. 经颅磁刺激对阿尔茨海默症治疗的效果观察[J]. 深圳中西医结合杂志, 2017, 27(7): 79-80.
18	吴越, 徐文炜, 刘晓伟, 等. 重复经颅磁刺激对阿尔茨海默病患者精神行为症状及认知功能的影响[J]. 中华物理医学与康复杂志, 2017, 39(2): 131-135.
19	徐春朝. 奥氮平联合重复经颅磁刺激治疗阿尔茨海默病精神行为症状[J]. 实用中西医结合临床, 2017, 17(8): 19-20.
20	邹扬. 经颅磁刺激在神经变性疾病诊断和治疗中作用的初步研究[D]. 上海: 上海交通大学, 2017.
21	Koch G, Bonnì S, Pellicciari MC, et al. Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease[J]. Neuroimage, 2018, 169: 302-311.
22	倪立, 华浩水, 邵建锋, 等. 重复经颅磁刺激辅助治疗对轻中度阿尔采默氏病患者认知功能和精神行为症状的疗效[J]. 全科医学临床与教育, 2019, 17(3): 216-219.
23	盛威, 杨雪, 吕凌, 等. 经颅磁刺激联合高压氧治疗对轻度认知功能障碍患者的疗效观察[J]. 健康大视野, 2019, (11): 52-53.
24	孙全勇. 应用重复经颅磁刺激治疗阿尔茨海默病的观察[J]. 医学美学美容, 2019, 28(12): 29.
25	王金东, 周田田, 陈晓芹, 等. 喹硫平联合颅磁刺激治疗老年痴呆精神行为症状的临床效果[J]. 中国医药导报, 2019, 16(17): 46-49.
26	张恒, 季荣霞, 李佳. 经颅磁刺激治疗阿尔茨海默病的临床疗效[J]. 中华物理医学与康复杂志, 2019, 41(1): 18-22.
27	梁宝今, 王晓文, 张晗, 等. 阿尔茨海默病患者经颅磁刺激治疗的meta分析[J]. 科技导报, 2017, 35(9): 95-99.
28	程健, 吴文. 高频重复经颅磁刺激治疗阿尔茨海默症效果的meta分析[J]. 实用医学杂志, 2016, 32(15): 2539-2543.
29	Bentwich J, Dobronevsky E, Aichenbaum S, et al. Beneficial effect of repetitive transcranial magnetic stimulation combined with cognitive training for the treatment of Alzheimer's disease: a proof of concept study[J]. J Neural Transm (Vienna), 2011, 118(3): 463-471.

Literature	Intervention method （Exp/Con）	Stimulation site	Number of treatment	Assessment scale	n （Exp/Con）	Outcome/score （Exp/Con）
Cotelli^［6］， 2008	TMS 20 Hz / sham stimulate	DLPFC	20 times	MMSE	5/5	（16.40±2.80）/（14.50±3.70）
Ahmed^［7］， 2012	TMS 20 Hz / sham stimulate	DLPFC	5 times	MMSE	10/6	（22.60±1.50）/（14.40±3.20）
	TMS 1 Hz / sham stimulate				11/5	（16.80±4.00）/（14.40±3.20）
	TMS 20 Hz / sham stimulate				5/2	（11.20±1.90）/（8.00±1.00）
	TMS 1 Hz / sham stimulate				4/2	（8.80±2.30）/（8.00±1.00）
Yang^［4］， 2014	（Donepezil+TMS 5 Hz） / Donepezil	Left prefrontal lobe	20 times	NPI	20/18	（16.69±6.62）/（23.44±5.49）
Rutherford^［8］， 2015	TMS 20 Hz / sham stimulate	Bilateral DLPFC	8 times	ADAS-Cog	6/10	（22.67±9.46）/（25.70±10.62）
Yin^［9］， 2015	（Oxiracetam+TMS 20 Hz） / Oxiracetam	Bilateral DLPFC	80 times	MMSE	30/30	（27.36±5.65）/（17.52±4.31）
Wu^［10］， 2015	（Risperidone+TMS 20 Hz） / （Risperidone+sham stimulate）	DLPFC	20 times	BEHAVE-AD，ADAS-Cog	26/26	BEHAVE-AD：（9.08±4.27）/（11.96±4.18）
						ADAS-Cog：（24.16±5.21）/（27.65±5.24）
Wu^［2］， 2015	TMS 20 Hz / sham stimulate	Bilateral DLPFC	20 times	ADAS-Cog	26/28	（20.10±5.20）/（27.90±10.20）
	TMS 1 Hz / sham stimulate				28/28	（23.10±5.30）/（27.90±10.20）
Guo^［11］， 2016	（Donepezil+TMS 15 Hz） / （Donepezil+sham stimulate）	Bilateral DLPFC	20 times	MMSE，ADAS-Cog	26/26	MMSE：（22.70±4.20）/（20.30±4.30）
						ADAS-Cog：（21.60±5.40）/（24.70±5.20）
Lee ^［12］， 2016	TMS 10 Hz / sham stimulate	DLPFC and parietal lobe	30 times	MMSE，ADAS-Cog	13/6	MMSE：（25.62±3.33）/（26.67±2.16）
					5/2	（19.40±3.98）/（18.00±5.66）
					13/6	ADAS-Cog：（16.31±6.40）/（18.17±4.54）
					5/2	（27.20±7.95）/（30.00±9.90）
Wu ^［13］， 2016	（Olanzapine+TMS 15 Hz） / （Olanzapine+sham stimulate）	Left DLPFC	20 times	MMSE，BEHAVE-AD	32/32	MMSE：（16.30±3.50）/（14.50±3.80）
						BEHAVE-AD：（12.10±4.10）/（14.60±5.30）
Fang ^［14］， 2017	（Galanthamine+rTMS） / Galanthamine	Bilateral DLPFC	18 times	MMSE	22/21	（7.80±0.42）/（3.57±0.13）
Liu ^［15］， 2017	TMS 15 Hz / sham stimulate	Bilateral DLPFC	60 times	MMSE，NPI	60/60	MMSE：（21.76±2.21）/（17.55±2.02）
	TMS 5 Hz / sham stimulate				60/60	（26.63±1.03）/（17.55±2.02）
	TMS 15 Hz / sham stimulate				60/60	NPI：（17.52±1.98）/（19.86±2.02）
	TMS 5 Hz / sham stimulate				60/60	（15.72±1.00）/（19.86±2.02）
Liu ^［16］，2017	TMS 10 Hz / sham stimulate	Left DLPFC	10 times	MMSE，NPI	12/10	MMSE：（18.91±2.87）/（18.25±4.36）
						NPI：（18.17±2.91）/（17.62±3.37）
Liang ^［17］，2017	（Conventional therapy+TMS 10 Hz） / conventional therapy	Bilateral prefrontal lobe	20 times	MMSE	34/34	（21.11±4.28）/（17.73±4.22）
			40 times			（27.19±4.56）/（23.49±5.01）
Wu ^［18］，2017	TMS 10 Hz / sham stimulate	Bilateral DLPFC	20 times	MMSE，BEHAVE-AD	24/24	MMSE：（16.89±4.30）/（13.92±3.68）
	TMS 1 Hz / sham stimulate				24/24	（14.50±4.13）/（13.92±3.68）
	TMS 10 Hz / sham stimulate				24/24	BEHAVE-AD：（10.12±3.31）/（13.29±4.07）
	TMS 1 Hz / sham stimulate				24/24	（12.87±4.16）/（13.29±4.07）
Xu ^［19］， 2017	（Olanzapine+TMS 15 Hz） / Olanzapine	Bilateral DLPFC	20 times	MMSE，BEHAVE-AD	40/40	MMSE：（22.60±1.01）/（19.45±0.77）
						BEHAVE-AD：（6.02±3.72）/（10.53±2.56）
Zou ^［20］， 2017	TMS 10 Hz / sham stimulate	Right DLPFC	10 times	MMSE	6/3	（26.30±2.60）/（27.70±1.50）
Koch^［21］， 2018	HF TMS / sham stimulate	PC	10 times	MMSE	14/14	（27.30±1.60）/（26.70±2.60）
Ni ^［22］， 2019	（Oxiracetam+Olanzapine+TMS 20 Hz） / （Oxiracetam+Olanzapine+sham stimulate）	Left DLPFC	20 times	BEHAVE-AD，ADAS-Cog	36/36	BEHAVE-AD：（9.08±4.27）/（11.96±4.18）
						ADAS-Cog：（24.16±5.21）/（27.65±5.24）
Sheng ^［23］， 2019	（Hyperbaric oxygen chamber +TMS 15 Hz） / Hyperbaric oxygen chamber	Bilateral frontal and temporal lobes	25 times	MMSE	42/38	（26.17±5.37）/（20.45±3.11）
Sun ^［24］， 2019	（Donepezil+TMS 15 Hz） / Donepezil	Bilateral DLPFC	20 times	MMSE	41/41	（22.90±4.30）/（20.30±4.20）
Wang ^［25］， 2019	（Quetiapine+TMS 5 Hz） / Quetiapine	Bilateral DLPFC	36 times	NPI	50/50	（13.28±1.65）/（15.67±1.98）
Zhang ^［26］， 2019	（Conventional therapy+TMS 5 Hz） / （conventional therapy+sham stimulate）	Bilateral DLPFC	28 times	MMSE，NPI	98/98	MMSE：（27.68±1.91）/（22.97±2.02）
						NPI：（13.69±1.13）/（19.69±1.02）

Literature	Intervention method （Exp/Con）	Stimulation site	Number of treatment	Assessment scale	n （Exp/Con）	Outcome/score （Exp/Con）
Cotelli^［6］， 2008	TMS 20 Hz / sham stimulate	DLPFC	20 times	MMSE	5/5	（16.40±2.80）/（14.50±3.70）
Ahmed^［7］， 2012	TMS 20 Hz / sham stimulate	DLPFC	5 times	MMSE	10/6	（22.60±1.50）/（14.40±3.20）
	TMS 1 Hz / sham stimulate				11/5	（16.80±4.00）/（14.40±3.20）
	TMS 20 Hz / sham stimulate				5/2	（11.20±1.90）/（8.00±1.00）
	TMS 1 Hz / sham stimulate				4/2	（8.80±2.30）/（8.00±1.00）
Yang^［4］， 2014	（Donepezil+TMS 5 Hz） / Donepezil	Left prefrontal lobe	20 times	NPI	20/18	（16.69±6.62）/（23.44±5.49）
Rutherford^［8］， 2015	TMS 20 Hz / sham stimulate	Bilateral DLPFC	8 times	ADAS-Cog	6/10	（22.67±9.46）/（25.70±10.62）
Yin^［9］， 2015	（Oxiracetam+TMS 20 Hz） / Oxiracetam	Bilateral DLPFC	80 times	MMSE	30/30	（27.36±5.65）/（17.52±4.31）
Wu^［10］， 2015	（Risperidone+TMS 20 Hz） / （Risperidone+sham stimulate）	DLPFC	20 times	BEHAVE-AD，ADAS-Cog	26/26	BEHAVE-AD：（9.08±4.27）/（11.96±4.18）
						ADAS-Cog：（24.16±5.21）/（27.65±5.24）
Wu^［2］， 2015	TMS 20 Hz / sham stimulate	Bilateral DLPFC	20 times	ADAS-Cog	26/28	（20.10±5.20）/（27.90±10.20）
	TMS 1 Hz / sham stimulate				28/28	（23.10±5.30）/（27.90±10.20）
Guo^［11］， 2016	（Donepezil+TMS 15 Hz） / （Donepezil+sham stimulate）	Bilateral DLPFC	20 times	MMSE，ADAS-Cog	26/26	MMSE：（22.70±4.20）/（20.30±4.30）
						ADAS-Cog：（21.60±5.40）/（24.70±5.20）
Lee ^［12］， 2016	TMS 10 Hz / sham stimulate	DLPFC and parietal lobe	30 times	MMSE，ADAS-Cog	13/6	MMSE：（25.62±3.33）/（26.67±2.16）
					5/2	（19.40±3.98）/（18.00±5.66）
					13/6	ADAS-Cog：（16.31±6.40）/（18.17±4.54）
					5/2	（27.20±7.95）/（30.00±9.90）
Wu ^［13］， 2016	（Olanzapine+TMS 15 Hz） / （Olanzapine+sham stimulate）	Left DLPFC	20 times	MMSE，BEHAVE-AD	32/32	MMSE：（16.30±3.50）/（14.50±3.80）
						BEHAVE-AD：（12.10±4.10）/（14.60±5.30）
Fang ^［14］， 2017	（Galanthamine+rTMS） / Galanthamine	Bilateral DLPFC	18 times	MMSE	22/21	（7.80±0.42）/（3.57±0.13）
Liu ^［15］， 2017	TMS 15 Hz / sham stimulate	Bilateral DLPFC	60 times	MMSE，NPI	60/60	MMSE：（21.76±2.21）/（17.55±2.02）
	TMS 5 Hz / sham stimulate				60/60	（26.63±1.03）/（17.55±2.02）
	TMS 15 Hz / sham stimulate				60/60	NPI：（17.52±1.98）/（19.86±2.02）
	TMS 5 Hz / sham stimulate				60/60	（15.72±1.00）/（19.86±2.02）
Liu ^［16］，2017	TMS 10 Hz / sham stimulate	Left DLPFC	10 times	MMSE，NPI	12/10	MMSE：（18.91±2.87）/（18.25±4.36）
						NPI：（18.17±2.91）/（17.62±3.37）
Liang ^［17］，2017	（Conventional therapy+TMS 10 Hz） / conventional therapy	Bilateral prefrontal lobe	20 times	MMSE	34/34	（21.11±4.28）/（17.73±4.22）
			40 times			（27.19±4.56）/（23.49±5.01）
Wu ^［18］，2017	TMS 10 Hz / sham stimulate	Bilateral DLPFC	20 times	MMSE，BEHAVE-AD	24/24	MMSE：（16.89±4.30）/（13.92±3.68）
	TMS 1 Hz / sham stimulate				24/24	（14.50±4.13）/（13.92±3.68）
	TMS 10 Hz / sham stimulate				24/24	BEHAVE-AD：（10.12±3.31）/（13.29±4.07）
	TMS 1 Hz / sham stimulate				24/24	（12.87±4.16）/（13.29±4.07）
Xu ^［19］， 2017	（Olanzapine+TMS 15 Hz） / Olanzapine	Bilateral DLPFC	20 times	MMSE，BEHAVE-AD	40/40	MMSE：（22.60±1.01）/（19.45±0.77）
						BEHAVE-AD：（6.02±3.72）/（10.53±2.56）
Zou ^［20］， 2017	TMS 10 Hz / sham stimulate	Right DLPFC	10 times	MMSE	6/3	（26.30±2.60）/（27.70±1.50）
Koch^［21］， 2018	HF TMS / sham stimulate	PC	10 times	MMSE	14/14	（27.30±1.60）/（26.70±2.60）
Ni ^［22］， 2019	（Oxiracetam+Olanzapine+TMS 20 Hz） / （Oxiracetam+Olanzapine+sham stimulate）	Left DLPFC	20 times	BEHAVE-AD，ADAS-Cog	36/36	BEHAVE-AD：（9.08±4.27）/（11.96±4.18）
						ADAS-Cog：（24.16±5.21）/（27.65±5.24）
Sheng ^［23］， 2019	（Hyperbaric oxygen chamber +TMS 15 Hz） / Hyperbaric oxygen chamber	Bilateral frontal and temporal lobes	25 times	MMSE	42/38	（26.17±5.37）/（20.45±3.11）
Sun ^［24］， 2019	（Donepezil+TMS 15 Hz） / Donepezil	Bilateral DLPFC	20 times	MMSE	41/41	（22.90±4.30）/（20.30±4.20）
Wang ^［25］， 2019	（Quetiapine+TMS 5 Hz） / Quetiapine	Bilateral DLPFC	36 times	NPI	50/50	（13.28±1.65）/（15.67±1.98）
Zhang ^［26］， 2019	（Conventional therapy+TMS 5 Hz） / （conventional therapy+sham stimulate）	Bilateral DLPFC	28 times	MMSE，NPI	98/98	MMSE：（27.68±1.91）/（22.97±2.02）
						NPI：（13.69±1.13）/（19.69±1.02）

Outcome	Limitation in design	Inconsistency	Indirectness	Imprecision	Publication bias	Quality
Cognitive function—assessed by ADAS-Cog
Subgroup
HF	Serious	No	No	Serious	Likely	⊕???very low
LF	Serious	No	No	No	Likely	⊕⊕??low
Cognitive function—assessed by MMSE
Subgroup 1
HF	Serious	Serious	No	Serious	Likely	⊕???very low
LF	Serious	No	No	Serious	Likely	⊕???very low
Subgroup 2
1 Hz	Serious	No	No	Serious	Likely	⊕???very low
5 Hz	Serious	Serious	No	Serious	Likely	⊕???very low
10 Hz	Serious	No	No	Serious	Likely	⊕???very low
15 Hz	Serious	Serious	No	Serious	Likely	⊕???very low
20 Hz	Serious	No	No	Serious	Likely	⊕???very low
Subgroup 3
≤5 times	No	No	No	Serious	Likely	⊕⊕??low
>5 times and ≤10 times	Serious	No	No	Serious	Likely	⊕???very low
>10 times and ≤20 times	Serious	Serious	No	Serious	Likely	⊕???very low
>20 times and ≤30 times	Serious	Serious	No	Serious	Likely	⊕???very low
>30 times and ≤40 times	Serious	No	No	No	Likely	⊕⊕??low
>40 times and ≤60 times	Serious	Serious	No	Serious	Likely	⊕???very low
>60 times and ≤80 times	Serious	No	No	No	Likely	⊕⊕??low
BPSD—assessed by NPI	Serious	Serious	No	Serious	Likely	⊕???very low
BPSD—assessed by BEHAVE-AD
Subgroup
HF	Serious	No	No	No	Likely	⊕⊕??low
LF	Serious	No	No	Serious	Likely	⊕???very low

Outcome	Limitation in design	Inconsistency	Indirectness	Imprecision	Publication bias	Quality
Cognitive function—assessed by ADAS-Cog
Subgroup
HF	Serious	No	No	Serious	Likely	⊕???very low
LF	Serious	No	No	No	Likely	⊕⊕??low
Cognitive function—assessed by MMSE
Subgroup 1
HF	Serious	Serious	No	Serious	Likely	⊕???very low
LF	Serious	No	No	Serious	Likely	⊕???very low
Subgroup 2
1 Hz	Serious	No	No	Serious	Likely	⊕???very low
5 Hz	Serious	Serious	No	Serious	Likely	⊕???very low
10 Hz	Serious	No	No	Serious	Likely	⊕???very low
15 Hz	Serious	Serious	No	Serious	Likely	⊕???very low
20 Hz	Serious	No	No	Serious	Likely	⊕???very low
Subgroup 3
≤5 times	No	No	No	Serious	Likely	⊕⊕??low
>5 times and ≤10 times	Serious	No	No	Serious	Likely	⊕???very low
>10 times and ≤20 times	Serious	Serious	No	Serious	Likely	⊕???very low
>20 times and ≤30 times	Serious	Serious	No	Serious	Likely	⊕???very low
>30 times and ≤40 times	Serious	No	No	No	Likely	⊕⊕??low
>40 times and ≤60 times	Serious	Serious	No	Serious	Likely	⊕???very low
>60 times and ≤80 times	Serious	No	No	No	Likely	⊕⊕??low
BPSD—assessed by NPI	Serious	Serious	No	Serious	Likely	⊕???very low
BPSD—assessed by BEHAVE-AD
Subgroup
HF	Serious	No	No	No	Likely	⊕⊕??low
LF	Serious	No	No	Serious	Likely	⊕???very low

[1]	Guo-qin HU, Cheng-qing YANG, Qin-yu LÜ, Jing ZHAO, Ming-huan ZHU, Zheng-hui YI, Xin-hai DAI. Effects of computerized cognitive correction therapy on cognitive function of schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(5): 622-627.
[2]	Wen-jun HUANG, Su-su JIANG, Min-fang TAO. Correlation between sleep quality and everyday cognitive function in perimenopausal and postmenopausal women [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2021, 41(4): 497-501.
[3]	PAN Sheng-ke, LI Hui, WEI Yan-yan, YAO Pei-fen, LI Hua-fang. Placebo effect in primary insomnia: a meta-analysis [J]. , 2020, 40(4): 505-.
[4]	HUANG Yan, ZHANG Xian-gao, LIN Heng, CHENG Shu-ying. Meta-analysis of effect and safety of repetitive transcranial magnetic stimulation on patients with schizophrenia [J]. , 2020, 40(1): 81-.
[5]	ZHOU Shao-yu1, FENG Zhen-xiao1, YAO Xiao-ping2, WANG Wan1, ZHAO Jing3#, YI Zheng-hui4#. Effects of typical or atypical antipsychotics on cognitive symptoms of the patients with schizophrenia [J]. JOURNAL OF SHANGHAI JIAOTONG UNIVERSITY (MEDICAL SCIENCE), 2020, 40(08): 1075-1080.
[6]	HONG Bo, HE Hai-ning, LIU Yuan-yuan, SU Ning, YAN Feng, SHI Yan-chen, WANG Jing-hua, WANG Tao, XIAO Shi-fu. One year follow-up study of sleep duration and cognitive function changes in the elderly with normal cognitive function [J]. , 2019, 39(9): 1017-.
[7]	WANG Dan-dan, ZHANG Chen. Research progress of neuroimmune mechanisms of cognitive function in schizophrenia and effect of atypical antipsychotic drugs on it [J]. , 2019, 39(7): 795-.
[8]	ZHU Li-na1, ZHANG Qiong2, CAI Jun1, ZHANG Wei-bo1, ZHU Hong-xia1. Effect of cerebellar vermal repetitive transcranial magnetic stimulation with theta burst stimulation paradigm on cognitive functions of patients with schizophrenia [J]. , 2019, 39(3): 282-.
[9]	WANG Ye-wei, CHEN Yan, FANG Xin-yu, ZHANG Yi, CAI Jun, SONG Li-sheng, ZHANG Chen. Association of serum olanzapine concentration and cytochrome P450 1A2 gene polymorphisms: a meta-analysis [J]. , 2019, 39(10): 1167-.
[10]	MAO Yi-ming, WEI Chang-jiang, WU Chang-jiang, QIN Yuan, LU Jia-hao, LU Wen-qiang. Comparison of efficacy of video-assisted thoracic surgery and conventional lung volume reduction surgery for the treatment of patients with severe chronic obstructive pulmonary disease: a meta-analysis [J]. , 2017, 37(7): 997-.
[11]	CHU Jing-jing, YE Chao, JIN Wen, YIN Xi . Robotic-assisted versus laparoscopic radical prostatectomy: a meta-analysis [J]. , 2017, 37(01): 64-.
[12]	Lü Wang-qiang, TANG Wei, CAI Jun, LU Wei-hong, YU Yue-guo, FAN Wei-xing, ZHANG Chen. Study on the effects of ANK3 gene on the development of cognitive impairment in patients with schizophrenia [J]. , 2016, 36(09): 1297-.
[13]	HUANG Xia, SONG Yan-yan. Correlation between smoking and incidence of Alzheimer's disease ——a systematic analysis of case-control studies and prevalence studies [J]. , 2015, 35(6): 870-.
[14]	CHEN Ping-ping, YANG Chen-min. Correlation between polymorphisms of DNA repair gene XRCC3 and ovarian cancer: a meta-analysis [J]. , 2015, 35(5): 718-.
[15]	ZHOU Ze-wen, PANG Ya-qin, QI Guang-zi, et al. Effects of occupational aluminum exposure on psychology, neural behaviors, cognitive function, and autonomic nervous function of workers [J]. , 2015, 35(2): 242-.